Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001214659-21-000683
Filing Date
2021-01-20
Accepted
2021-01-20 18:18:04
Documents
1
Period of Report
2021-01-15

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-50975.html 4  
1 PRIMARY DOCUMENT marketforms-50975.xml 4 5790
  Complete submission text file 0001214659-21-000683.txt   7221
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Issuer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O MIRATI THERAPEUTICS, INC. 9393 TOWNE CENTRE DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address
Christensen Jamie (Reporting) CIK: 0001599324 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35921 | Film No.: 21539866